Monopar Therapeutics MNPR Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's total equity?
- Monopar Therapeutics (MNPR) reported total equity of $135.39M in Q1 2026.
- How has Monopar Therapeutics's total equity changed year-over-year?
- Monopar Therapeutics's total equity increased by 152.6% year-over-year, from $53.59M to $135.39M.
- What is the long-term trend for Monopar Therapeutics's total equity?
- Over 5 years (2020 to 2025), Monopar Therapeutics's total equity has grown at a 54.4% compound annual growth rate (CAGR), from $15.69M to $137.83M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.